sacituzumab govitecan-hziy news

All news on sacituzumab govitecan-hziy (also known as Trodelvy): plants, production capacities, investments and involved companies.

8 June 2026

Merck and Gilead discontinue Phase 3 KEYNOTE‑D46/EVOKE‑03 (Trodelvy + KEYTRUDA) in PD‑L1 ≥50% mNSCLC

eDMC recommended stopping the Phase 3 trial after final PFS and interim OS reviews: PFS trend non‑significant, OS unlikely to be significant; safety profile consistent; ~620 patients enrolled.

Who will be producing sacituzumab govitecan-hziy in the future?

Find out with chemXplore Alpha

Learn more